Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fallopian Tube Neoplasms: full-pipeline trial registry
3 of 12 indexed Fallopian Tube Neoplasms trials are currently recruiting.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Fallopian Tube Neoplasms: 12 US clinical trials tracked, 3 recruiting.
Fallopian Tube Neoplasms is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 2 of these trials.
Enrollment posture brief
Registry condition fallopian-tube-neoplasms
OPEN 3 | RECR 25% | LATE 6 | EARLY 4 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Fallopian Tube Neoplasms lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fallopian Tube Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fallopian Tube Neoplasms is recruiting below its size-band peers.
3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Fallopian Tube Neoplasms research.
Eli Lilly and Company accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Fallopian Tube Neoplasms enrolment sits around 250 participants.
Median target enrolment is 250 among the 12 trials that report a genuine target (sentinel values excluded). 3 of those (25%) plan for fewer than 100 participants.
-
Fallopian Tube Neoplasms research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Eli Lilly and Company
NCT07213804
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Massachusetts General Hospital
NCT04794322
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings
NCT04196257
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Merck Sharp & Dohme
NCT05116189
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio
NCT04498117
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
NCT05257408
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences
NCT05617755
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development
NCT01846611
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
NCT00191607
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Pierian Biosciences
NCT00443196
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
University of Michigan
NCT02444195
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Novartis Pharmaceuticals
NCT00035100
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Fallopian Tube Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fallopian Tube Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fallopian Tube Neoplasms page
12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Fallopian Tube Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Fallopian Tube Neoplasms trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fallopian Tube Neoplasms condition card totals 12 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.